¼¼°èÀÇ µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ ½ÃÀå ÀλçÀÌÆ®, ¿¹Ãø(-2031³â)
Global Dual Orexin Receptor Antagonist Market Insights, Forecast to 2031
»óǰÄÚµå : 1693151
¸®¼­Ä¡»ç : QYResearch
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,953,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,350 £Ü 10,430,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ³»¿ëÀÇ ÅØ½ºÆ® µîÀ» Copy & Paste ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 9,800 £Ü 13,907,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ ½ÃÀå ±Ô¸ð´Â 2024³â 6¾ï 7,085¸¸ ´Þ·¯¿¡¼­ 2031³â±îÁö 12¾ï 3,497¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£¿¡ CAGR·Î 7.14%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

¹Ì±¹¡¤Ä³³ª´Ù ½ÃÀå ±Ô¸ð´Â 2024³â 1¾ï 4,576¸¸ ´Þ·¯¿¡¼­ 2031³â±îÁö 1¾ï 6,232¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2025-2031³âÀÇ ¿¹Ãø ±â°£ÀÇ CAGRÀº 0.61%ÀÔ´Ï´Ù.

ÀϺ» ½ÃÀå ±Ô¸ð´Â 2024³â 4¾ï 3,187¸¸ ´Þ·¯¿¡¼­ 2031³â±îÁö 7¾ï 711¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2025-2031³âÀÇ ¿¹Ãø ±â°£ÀÇ CAGRÀº 5.18%ÀÔ´Ï´Ù.

À¯·´ ½ÃÀå ±Ô¸ð´Â 2024³â 7,935¸¸ ´Þ·¯¿¡¼­ 2031³â±îÁö 3¾ï 4,307¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2025-2031³âÀÇ ¿¹Ãø ±â°£ÀÇ CAGRÀº 18.23%ÀÔ´Ï´Ù.

¼¼°è µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü´Â Merck, Eisal, Idorsia µîÀÔ´Ï´Ù. 2024³â, ¼¼°è »óÀ§ 2»çÀÇ ¸ÅÃâ Á¡À¯À²Àº ¾à 83.43%¿´½À´Ï´Ù.

¼¼°èÀÇ µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, °¢ Áö¿ªÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÁÖ¿ä ±â¾÷ÀÇ ¼øÀ§, ½ÃÀå Á¡À¯À² µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå °¢ Á¦Á¶¾÷üÀÇ °æÀï

Á¦4Àå ½ÃÀå ±Ô¸ð : À¯Çüº°

Á¦5Àå ½ÃÀå ±Ô¸ð : ¿ëµµº°

Á¦6Àå ¹Ì±¹¡¤Ä³³ª´Ù

Á¦7Àå À¯·´

Á¦8Àå ÀϺ»

Á¦9Àå ½Î¿ò

Á¦10Àå ±â¾÷ °³¿ä

Á¦11Àå »ê¾÷ üÀΰú ÆÇ¸Åä³ÎÀÇ ºÐ¼®

Á¦12Àå µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ ½ÃÀå ¿ªÇÐ

Á¦13Àå ¼¼°èÀÇ µà¾ó ¿À·º½Å ¼ö¿ëü ±æÇ×Á¦ ¿¬±¸¿¡¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú

Á¦14Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Dual Orexin Receptor Antagonist market is projected to grow from US$ 670.85 million in 2024 to US$ 1,234.97 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.14% during the forecast period.

The United States & Canada market for Dual Orexin Receptor Antagonist is estimated to increase from $ 145.76 million in 2024 to reach $162.32 million by 2031, at a CAGR of 0.61% during the forecast period of 2025 through 2031.

The Japan market for Dual Orexin Receptor Antagonist is estimated to increase from $ 431.87 million in 2024 to reach $707.11 million by 2031, at a CAGR of 5.18% during the forecast period of 2025 through 2031.

The Europe market for Dual Orexin Receptor Antagonist is estimated to increase from $ 79.35 million in 2024 to reach $343.07 million by 2031, at a CAGR of 18.23% during the forecast period of 2025 through 2031.

The global key manufacturers of Dual Orexin Receptor Antagonist include Merck, Eisal, Idorsia, etc. In 2024, the global top two players had a share approximately 83.43% in terms of revenue.

Report Includes

This report presents an overview of global market for Dual Orexin Receptor Antagonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Dual Orexin Receptor Antagonist, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Dual Orexin Receptor Antagonist, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dual Orexin Receptor Antagonist sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2024. Identification of the major stakeholders in the global Dual Orexin Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dual Orexin Receptor Antagonist sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Merck, Eisal, Idorsia, etc.

Market Segmentation

By Company

Segment by Type

Segment by Application

Segment by Region

US & Canada

Europe

Japan

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Dual Orexin Receptor Antagonist in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 3: Detailed analysis of Dual Orexin Receptor Antagonist manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.

Chapter 7: Europe by Type, and by Application, sales, and revenue for each segment.

Chapter 8: Japan by Type, and by Application, sales, and revenue for each segment.

Chapter 9: ROW by Type, and by Application, sales, and revenue for each segment.

Chapter 10: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dual Orexin Receptor Antagonist sales, revenue, price, gross margin, and recent development, etc.

Chapter 11: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 12: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 13: The main points and conclusions of the report.

Table of Contents

1 STUDY COVERAGE

2 EXECUTIVE SUMMARY

3 COMPETITION BY MANUFACTURERS

4 MARKET SIZE BY TYPE

5 MARKET SIZE BY APPLICATION

6 US & CANADA

7 EUROPE

8 JAPAN

9 ROW

10 CORPORATE PROFILE

11 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS

12 DUAL OREXIN RECEPTOR ANTAGONIST MARKET DYNAMICS

13 KEY FINDINGS IN THE GLOBAL DUAL OREXIN RECEPTOR ANTAGONIST STUDY

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â